Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104558 | 0.85 | SCN3A (0.45) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL1104559 | 0.85 | SCN3A (0.45) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL2833514 | 0.76 | KCNH2 (0.51) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL2835553 | 0.76 | SCN3A (0.49) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL1107970 | 0.76 | SCN3A (0.51) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL13320316 | 0.75 | KCNH2 (0.49) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL14041369 | 0.75 | KCNH2 (0.49) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL1104554 | 0.75 | KCNH2 (0.49) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL13320312 | 0.75 | KCNH2 (0.51) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL13320320 | 0.74 | KCNH2 (0.48) | SCN3AKCNH2SCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | SCN3A 2696/4885KCNH2 3260/4885SCN1A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.